ADRB2 and stage 5 chronic kidney disease: Diabetic kidney disease (DKD) is the most common cause of end-stage renal disease [7], and this review explores the beneficial role of β2-AR agonists in DKD and summarizes the different mechanisms by which these drugs act, as postulated by various studies.